Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Monday. A ...

Teva’s Austedo guidance for 2025, at $1.9 billion to $2 billion, currently stands lower than Neurocrine's Ingrezza range. While “both brands are doing quite well,” according to Neurocrine ...

Of the trio, the most drastic cutter was UBS's Ashwani Verma, who reduced his level on Neurocrine to $154 per share from his preceding $176. According to reports, Verma cited uninspiring guidance ...

Wedbush analyst Laura Chico lowered the firm’s price target on Neurocrine (NBIX) to $147 from $157 and keeps an Outperform rating on the shares. With Ingrezza falling short of Q4 expectations ...

On Thursday, Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56. The company ...

It's been a soft week for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares, which are down 19%. But we wouldn't complain about the gain over the last three years. In that time the stock gained 43 ...

State of Alaska Department of Revenue cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates. Overall, the quarter showcased strong ...

Neurocrine Biosciences Q4 EPS of $1.69 beat estimates, while revenue missed consensus. Ingrezza sales rose 23% to $615 million. 2025 Ingrezza sales guidance fell short of Street estimate. Analysts ...